BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
2024年4月22日 - 7:45PM
BioNTech to Report First Quarter 2024 Financial Results and
Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE)
-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”)
will announce its financial results for the first quarter 2024 on
Monday, May 6, 2024. Additionally, the Company will host a
conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m.
CEST) for investors, financial analysts and the general public to
discuss its financial results and provide a corporate update.
To access the live conference call via
telephone, please register via this link. Once registered, dial-in
numbers and a PIN will be provided. It is recommended to register
at least one day in advance. The slide presentation and audio of
the webcast will be available via this link.
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page in the Investor Relations section of the Company’s website
at https://biontech.com/. A replay of the webcast will be made
available shortly after the call and archived on the Company’s
website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is
a global next generation immunotherapy company pioneering novel
therapies for cancer and other serious diseases. BioNTech exploits
a wide array of computational discovery and therapeutic drug
platforms for the rapid development of novel biopharmaceuticals.
Its broad portfolio of oncology product candidates includes
individualized and off-the-shelf mRNA-based therapies, innovative
chimeric antigen receptor (CAR) T cells, several protein-based
therapeutics, including bispecific immune checkpoint modulators,
targeted cancer antibodies and antibody-drug conjugate (ADC)
therapeutics, as well as small molecules. Based on its deep
expertise in mRNA vaccine development and in-house manufacturing
capabilities, BioNTech and its collaborators are developing
multiple mRNA vaccine candidates for a range of infectious diseases
alongside its diverse oncology pipeline. BioNTech has established a
broad set of relationships with multiple global and specialized
pharmaceutical collaborators, including Biotheus, DualityBio, Fosun
Pharma, Genentech, a member of the Roche Group, Genevant, Genmab,
OncoC4, Pfizer and Regeneron.
For more information, please visit
www.BioNTech.com. CONTACTS
Investor RelationsVictoria Meissner, M.D.+1 617 528
8293Investors@biontech.de
Media Relations Jasmina Alatovic +49 (0)6131 9084 1513
Media@biontech.de
BioNTech (TG:22UA)
過去 株価チャート
から 6 2024 まで 7 2024
BioNTech (TG:22UA)
過去 株価チャート
から 7 2023 まで 7 2024